NASDAQ:CSIICardiovascular Systems Stock Price, Forecast & News

Cardiovascular Systems' stock was trading at $36.32 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CSII shares have increased by 7.1% and is now trading at $38.91. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cardiovascular Systems.

Cardiovascular Systems is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Cardiovascular Systems.

Cardiovascular Systems Inc (NASDAQ:CSII) announced its quarterly earnings results on Tuesday, May, 5th. The medical device company reported ($0.08) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.09) by $0.01. The medical device company had revenue of $61.18 million for the quarter, compared to analyst estimates of $64 million. Cardiovascular Systems had a negative net margin of 4.04% and a negative return on equity of 7.36%. View Cardiovascular Systems' earnings history.

6 Wall Street analysts have issued 1-year target prices for Cardiovascular Systems' stock. Their forecasts range from $45.00 to $58.00. On average, they expect Cardiovascular Systems' share price to reach $49.60 in the next twelve months. This suggests a possible upside of 27.5% from the stock's current price. View analysts' price targets for Cardiovascular Systems.

Press coverage about CSII stock has been trending somewhat positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cardiovascular Systems earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave media coverage about the medical device company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutCardiovascular Systems.

Cardiovascular Systems saw a increase in short interest in April. As of April 30th, there was short interest totaling 1,490,000 shares, an increase of 5.7% from the April 15th total of 1,410,000 shares. Based on an average trading volume of 328,400 shares, the days-to-cover ratio is currently 4.5 days. Approximately 4.4% of the company's shares are sold short. View Cardiovascular Systems' Current Options Chain.

Some companies that are related to Cardiovascular Systems include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Steris (STE) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiovascular Systems investors own include AbbVie (ABBV), Gilead Sciences (GILD), Netflix (NFLX), Adobe (ADBE), Advanced Micro Devices (AMD), Activision Blizzard (ATVI), Medtronic (MDT), Pfizer (PFE), Procter & Gamble (PG) and Target (TGT).

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

Cardiovascular Systems' stock is owned by many different retail and institutional investors. Top institutional shareholders include Brown Capital Management LLC (16.63%), BlackRock Inc. (15.82%), Champlain Investment Partners LLC (7.63%), Janus Henderson Group PLC (3.84%), Wellington Management Group LLP (3.81%) and State Street Corp (3.49%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Jeffrey S Points, Martha Goldberg Aronson, Sandra Sedo and Scott R Ward. View institutional ownership trends for Cardiovascular Systems.

CSII stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Morgan Stanley, Morgan Stanley, Russell Investments Group Ltd., Parametric Portfolio Associates LLC, Acadian Asset Management LLC, State Board of Administration of Florida Retirement System, and First Trust Advisors LP. Company insiders that have sold Cardiovascular Systems company stock in the last year include Alexander Rosenstein, and Sandra Sedo. View insider buying and selling activity for Cardiovascular Systems.

CSII stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Peregrine Capital Management LLC, Champlain Investment Partners LLC, Balyasny Asset Management LLC, Invesco Ltd., BlackRock Inc., Assenagon Asset Management S.A., and Nuveen Asset Management LLC. Company insiders that have bought Cardiovascular Systems stock in the last two years include Martha Goldberg Aronson, and Scott R Ward. View insider buying and selling activity for Cardiovascular Systems.

Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CSII stock can currently be purchased for approximately $38.91.

Cardiovascular Systems has a market capitalization of $1.37 billion and generates $248.02 million in revenue each year. The medical device company earns $-250,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Cardiovascular Systems employs 652 workers across the globe.

The official website for Cardiovascular Systems is www.csi360.com.

Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]